PriceTargets.com logo

Organigram - OGI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.86 As of 04/25/2024 05:00 PM ET
▼ -0.07 (-3.63%)

This chart shows the closing price for OGI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organigram Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Organigram in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.86.

This chart shows the closing price for OGI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Organigram. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2024Alliance Global PartnersUpgradeNeutral ➝ BuyLow
1/13/2023Stifel NicolausUpgradeHold ➝ BuyLow
1/11/2023Raymond JamesLower TargetC$12.00 ➝ C$8.00Low
7/15/2022Stifel NicolausLower TargetC$9.00 ➝ C$6.00Low
7/15/2022Alliance Global PartnersLower TargetC$9.00 ➝ C$6.00Low
4/12/2022Atb Cap MarketsUpgradeSector Perform ➝ OutperformMedium
1/13/2022Stifel NicolausLower TargetC$11.00 ➝ C$9.00Medium
1/12/2022Canaccord Genuity GroupUpgradeHold ➝ BuyC$12.00 ➝ C$13.00Medium
1/12/2022Cantor FitzgeraldLower TargetOverweight$22.80 ➝ $21.20Medium
12/8/2021Cantor FitzgeraldBoost TargetOverweight$22.00 ➝ $22.80Medium
11/23/2021Alliance Global PartnersLower TargetPositive ➝ NeutralC$15.00 ➝ C$12.00Medium
9/23/2021CIBCLower TargetNeutralC$16.00 ➝ C$14.00Low
7/23/2021Atb Cap MarketsReiterated RatingSector PerformHigh
7/15/2021Stifel NicolausLower TargetHoldC$16.00 ➝ C$15.00Low
7/14/2021CIBCBoost TargetNeutralC$15.00 ➝ C$16.00Low
7/9/2021CIBCReiterated RatingHold$15.00Low
6/11/2021CIBCBoost TargetNeutralC$13.00 ➝ C$15.00Medium
5/11/2021CIBCUpgradeSector Underperform ➝ NeutralHigh
4/20/2021CIBCReiterated RatingNeutral ➝ Underperformer$20.00 ➝ $13.00High
4/15/2021Stifel NicolausBoost TargetHold$16.00 ➝ $24.00Medium
4/14/2021Raymond JamesLower TargetOutperform$24.00 ➝ $20.00Medium
4/14/2021CIBCDowngradeNeutral ➝ Sector Underperform$20.00 ➝ $13.00High
4/13/2021Alliance Global PartnersLower TargetNeutral$16.00 ➝ $15.00High
4/8/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$16.00Medium
3/16/2021Stifel NicolausBoost TargetHold$7.60 ➝ $24.00Low
3/16/2021BMO Capital MarketsReiterated RatingMarket Perform ➝ Underperform$8.00High
3/12/2021CIBCBoost TargetNeutral$17.00 ➝ $20.00Low
3/12/2021Raymond JamesBoost TargetOutperform$12.00 ➝ $24.00Low
3/11/2021Cantor FitzgeraldReiterated RatingOverweight$14.00 ➝ $24.00High
3/11/2021Alliance Global PartnersReiterated RatingNeutralHigh
3/10/2021BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$8.00High
2/22/2021CIBCBoost TargetNeutral$9.00 ➝ $17.00High
1/13/2021Alliance Global PartnersDowngradeBuy ➝ NeutralMedium
1/12/2021Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
12/4/2020Cantor FitzgeraldLower TargetOverweight$21.40 ➝ $12.00High
12/1/2020CIBCBoost TargetNeutral$8.00 ➝ $9.00High
9/17/2020Cantor FitzgeraldReiterated RatingBuy$21.40Medium
8/10/2020Jefferies Financial GroupReiterated RatingBuy$15.16High
7/22/2020CIBCLower TargetNeutral$11.00 ➝ $8.00High
7/22/2020Stifel NicolausDowngradeBuy ➝ Hold$7.00Medium
7/21/2020Pi FinancialReiterated RatingBuyMedium
7/21/2020AltaCorp CapitalDowngradeOutperform ➝ Sector PerformHigh
7/21/2020OppenheimerReiterated RatingHoldHigh
7/7/2020Alliance Global PartnersInitiated CoverageBuy$16.00Medium
6/29/2020Raymond JamesDowngradeOutperform ➝ Market PerformMedium
6/16/2020OppenheimerInitiated CoverageHoldMedium
5/29/2020Raymond JamesReiterated RatingBuyMedium
4/15/2020CIBCDowngradeOutperform ➝ Neutral$20.00 ➝ $11.00Low
4/14/2020AltaCorp CapitalUpgradeSector Perform ➝ OutperformLow
4/14/2020Cantor FitzgeraldLower TargetOverweight$23.20 ➝ $22.40Low
4/1/2020Cantor FitzgeraldLower TargetOverweight$36.00 ➝ $23.20High
3/19/2020Bank of AmericaUpgradeHold$6.88High
3/19/2020CitigroupUpgradeUnderperform ➝ NeutralMedium
1/15/2020Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
1/13/2020Bank of AmericaInitiated CoverageUnderperformHigh
1/8/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
11/26/2019AltaCorp CapitalDowngradeOutperform ➝ Sector PerformLow
11/25/2019Beacon SecuritiesDowngradeBuy ➝ HoldHigh
11/12/2019BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
11/5/2019Cantor FitzgeraldInitiated CoverageOverweight$68.40High
10/17/2019Paradigm CapitalSet TargetBuy$34.00Low
10/11/2019Jefferies Financial GroupUpgradeHold ➝ Buy$32.80High
9/24/2019CIBCInitiated CoverageOutperformer$36.00High
9/18/2019Raymond JamesInitiated CoverageBuyLow
9/5/2019OppenheimerInitiated CoverageMarket PerformHigh
7/15/2019Pi FinancialSet TargetBuy$48.00High
5/3/2019Jefferies Financial GroupDowngradeBuy ➝ HoldLow
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Organigram logo
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $1.86
Low: $1.84
High: $1.91

50 Day Range

MA: $2.09
Low: $1.83
High: $2.72

52 Week Range

Now: $1.86
Low: $0.97
High: $2.91

Volume

858,148 shs

Average Volume

1,358,161 shs

Market Capitalization

$191.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Organigram?

The following Wall Street sell-side analysts have issued reports on Organigram in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for OGI.

What is the current price target for Organigram?

0 Wall Street analysts have set twelve-month price targets for Organigram in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Organigram in the next year.
View the latest price targets for OGI.

What is the current consensus analyst rating for Organigram?

Organigram currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OGI will outperform the market and that investors should add to their positions of Organigram.
View the latest ratings for OGI.

What other companies compete with Organigram?

Other companies that are similar to Organigram include Rigel Pharmaceuticals, Zevra Therapeutics, Trevi Therapeutics, Design Therapeutics and Lifecore Biomedical. Learn More about companies similar to Organigram.

How do I contact Organigram's investor relations team?

Organigram's physical mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company's listed phone number is (844) 644-4726. The official website for Organigram is www.organigram.ca. Learn More about contacing Organigram investor relations.